Ai Technology Group INC

AI Technology Group Inc. has amended its merger agreement with AVM Biotechnology and Biomed 360, extending the closing date to December 31, 2026, to accommodate financial audit requirements.

AI Technology Group Inc. filed an amendment to its 8-K, updating details of its acquisition of AVM Biotechnology Inc., including an increase in convertible debentures.

AI Technology Group Inc. amended its merger agreement with AVM Biotechnology Inc. and Biomed 360 Solutions Corp., extending the closing date to July 26, 2026, and revising investment tranches.

AI Technology Group Inc. announced plans to change its name to AVM Biotechnology, Inc., pending FINRA review.

AI Technology Group Inc. has amended its merger agreement with AVM Biotechnology Inc. and Biomed 360 Solutions Corp., extending the closing date and revising investment tranches due to financial audit obligations.

AI Technology Group Inc. and AVM Biotechnology Inc. announced an extension of funding dates for their proposed merger and the re-commencement of AVM's FDA Phase 2 Clinical Trial for AVM0703.

AI Technology Group Inc. filed an amended quarterly report revealing increased operating losses, a significant working capital deficit, and substantial doubt about its ability to continue as a going concern.

AI Technology Group Inc. reported a significant increase in net loss for Q3 2025, driven by operational expenses, while pursuing an acquisition and facing going concern doubts.

AI Technology Group Inc. President and Director Marcus Johnson acquired 265 shares of common stock, signaling continued confidence in the company.